RESEARCH AREA

Parkinson's Disease

Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominantly dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.

Clinical Trials Currently Ongoing

BN42358 PADOVA (Hoffmann-La Roche)

Victorine Sikati Foko Recruitment is closed

BIA 28-6156-201 ACTIVATE (Bial R&D Investments)

Victorine Sikati Foko Recruitment is closed

Completed Clinical Trials

2023 BIAL (Phase II)
2021: BN42358 study (Phase IIb)
2014: iSTEP study (Phase III)
2011: CONFIDENT-PD study (Phase II)
2010: AFQ056A2217 study (Phase II)
2010: AFQ056A2208 study (Phase II)

Symptoms & Cause

Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:

Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible

The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.

Diagnose & Treatment

There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.

There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.

There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.

Importance of clinical research

Scientists and doctors are working together to find a treatment or prevention technique. The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why. We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple SclerosisStrokeParkinson’sAlzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective. Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves. When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.

Maladie de Parkinson

La recherche sur la maladie de Parkinson a fait d’immenses progrès au cours des dernières décennies. Les travaux vont d’une meilleure compréhension des mécanismes sous-jacents et de l’optimisation des traitements symptomatiques à des interventions visant à ralentir ou à stopper la progression de la maladie.

ESSAIS CLINIQUES

La CNO participe à des essais cliniques évaluant des thérapies dont l’objectif est de ralentir ou d’arrêter la progression de la maladie.

Études en recrutement

Veuillez vous informer. Au moment de la rédaction, la CNO n’a pas d’essai en recrutement.

Études en cours

Padova OLE
Victorine Sikati Foko Recrutement terminé closed
 
BIA 28-6156-201/ Activate
Contact Victorine Sikati Foko Recrutement terminé

Études terminées

Our Services Include:

About rTMS for Parkinson’s Disease:

Transcranial magnetic stimulation (rTMS) is a non-invasive technique that uses targeted magnetic pulses to modulate brain activity. Research studies (see published articles) suggest it may help alleviate symptoms such as:

While promising, rTMS remains an experimental treatment for Parkinson’s Disease and is not currently covered by public health insurance (RAMQ/OHIP).

Completed